Optimal Therapies for Relapsed/Refractory Multiple Myeloma

EP: 1.Breakthroughs in Therapeutic Options for Relapsed/Refractory Multiple Myeloma

EP: 2.Highlights From the 2021 European Hematology Association Congress on Multiple Myeloma

EP: 3.Upcoming Abstracts on Multiple Myeloma for Presentation at 2021 ASH

EP: 4.Biggest FDA News for Multiple Myeloma in 2021

EP: 5.Treatment Options for Transplant-Eligible Multiple Myeloma

EP: 6.Treatment Options for Transplant-Ineligible Multiple Myeloma

EP: 7.Navigating Individual Treatment for Relapsed/Refractory Multiple Myeloma

EP: 8.Understanding Adverse Events in Multiple Myeloma

EP: 9.BCMA-Directed Agents for Multiple Myeloma

Now Viewing

EP: 10.Optimal Therapies for Relapsed/Refractory Multiple Myeloma

EP: 11.Emerging Research and Therapies for Multiple Myeloma

EP: 12.Upcoming Phase 3 Data in Multiple Myeloma

EP: 13.Trials Evaluating Emerging Maintenance Therapy Regimens in Multiple Myeloma

EP: 14.Looking Ahead to the Future of Multiple Myeloma Treatment

EP: 15.Current Leading Therapies for Multiple Myeloma

Nina Shah, MD: For patients with relapsed or refractory myeloma, choosing the most optimal therapy depends on what they had before and what they tolerated. In the earlier lines, the go-to therapy has been a CD38 monoclonal antibody in combination with something. We cannot ignore the very impressive data that has been shown by CD38 monoclonal antibody therapy in combination with carfilzomib [Kyprolis], both from the CANDOR study [NCT03158688] and IKEMA study [NCT03275285]. [We saw] impressive progression-free survival data there. That’s starting to take hold a lot more, especially for patients with aggressive early relapses.

In the later relapses, I’m very impressed with the BCMA [B-cell maturation antigen] CAR T-cell therapy and the BCMA bispecific T-cell engager data. There’s also a potential role for the novel CELMoDs [cereblon E3 ligase modulators] if you incorporate them in combination. Then finally, there are drugs like selinexor [Xpovio] that can be used particularly in combination with other drugs that a patient may have seen long time ago but is ready to be exposed to [again].